



**Supplementary Figure 3.** Kaplan-Meier estimates of overall survival defined as time from atezolizumab plus bevacizumab initiation to death (Vp1-3). HCC, hepatocellular carcinoma; PVTT, portal vein tumor thrombosis; RT, radiation therapy.